Amoxicillin in the treatment of urogenital chlamydia in pregnant women

C.trachomatis is the most common causative agent of sexually transmitted infections. For the treatment of urogenital chlamydia in pregnant women, various drugs are currently used erythromycin, spiramycin, josamycin and amoxicillin. Despite the fact that amoxicillin is mentioned in almost all recommendations for the treatment of STDs, it is very rare to find links to studies devoted to this question.

From May 1985 to April 1988 Crombleholme and colleagues conducted a prospective open comparative study on erythromycin (500 mg 4 times daily for 7 days) and amoxicillin (500 mg 3 times daily for 7 days) for treatment of urogenital chlamydia in pregnant women. The study included 193 pregnant women with a culture-confirmed method of chlamydia infection. The final analysis included 64 women from the amoxicillin group (group 1) and 58 from the erythromycin group (group 2). In group 1, the microbiological efficiency was 98.4% (63/64), while in group 2 - 94.8% (55/58) (the differences were not statistically significant). The vertical route of mother-to-child transmission was assessed by cultural and serological methods. The results were comparable in the two groups. In 94.9% (37/39) of the newborns in group 1 and 88.8% (32/36) of the newborns in the second group, no chlamydia infection was detected. The incidence of NLR in the erythromycin group was comparable to that in the amoxicillin group (15 and 8%, respectively). However, the rate of erythromycin withdrawal due to the development of NLR was higher than amoxicillin (13 and 2%, respectively, p less than 0.006).

Thus, based on the data from these studies, amoxicillin is currently one of the drugs of choice for the treatment of urogenital chlamydia in pregnant women.